Despite increasing publicity, “personalized medicine” is not a new phenomenon in cancer care. Oncologists have long used criteria such as body size, performance status, comorbid conditions, organ function, lifestyle, and a patient’s goals of care to individualize treatment decisions and drug doses. Additionally, dose adjustments of 1 or more agents [ Read More ]
Navin Pinto, MD
Dr Pinto is in the department of pediatrics, section of hematology/oncology at the University of Chicago. He participates on the committee for clinical pharmacology and pharmacogenomics at the University of Chicago.
In the News
May 17, 2016